Impact of three months of rosuvastatin treatment on peripheral endothelial function, inflammatory markers in the blood and the skeletal muscle and on postnatal vasculogenesis in patients with severe chronic heart failure
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2011
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- 30 Jul 2007 Status changed from recruiting to completed.
- 20 Nov 2005 New trial record.